Why BGPT?
logo

Assess an author's data and outputs

See the raw experimental evidence behind an author's publications and reproducibility signals.







Press Enter ↵ to solve



    Fuel Your Discoveries




     Quick Explanation


    Aikaterini Ziogou — evidence-weighted assessment: based on the provided publication record, the strongest signal is co-authorship on a high-impact Nature study linking FSP1 (and parallel ferroptosis suppression axes) to ferroptosis and tumor control in KRAS-driven lung adenocarcinoma models ().



     Long Explanation


    Author Review (Science Strength): Aikaterini Ziogou
    Date context: March 27, 2026 • Evidence scope: only the provided paper records + explicit metadata/excerpts you supplied.
    Citation & output trend (from provided OpenAlex snapshot)
    This figure uses only the counts you provided (2025–2026). It is not a substitute for full bibliometrics.
    Top cited works (provided record)
    Only works explicitly listed in your input are included.
    1) Evidence-weighted scientific strength (what Ziogou’s record most strongly supports)
    Core high-impact signal (Nature paper)
    • The Nature study reports that targeting ferroptosis-suppressing mechanisms—including FSP1 and GPX4 axes—triggers ferroptosis and suppresses tumor growth in KRAS-driven lung adenocarcinoma (LUAD) in vivo contexts, and it reports therapeutic targeting with icFSP1 extending survival and reducing tumor burden across LUAD-relevant model types (GEMMs, xenografts, and PDX in the provided excerpt).
    Basis:
    Mechanistic scope & molecular endpoints (from your excerpt)
    • Your excerpt indicates use of ferroptosis-linked biomarkers and lipid oxidation readouts, including LC-MS lipidomics (with mention of oxidized lipid species), and protein/lipid markers such as GPX4 and FSP1, along with tumor burden, cell death assays, and imaging.
    • The study also positions FSP1 as predictive of better targeting, using LUAD expression/clinical association analyses in addition to in vivo dependency tests (as described in your excerpt).
    Basis:
    Additional supporting paper in the provided record (PNAS 2026)
    • A second provided record (PNAS 2026) concerns T-cell phospholipid profiles shaping ACSL4 dependency and ferroptosis sensitivity across naive/effector/memory T-cell states, with Ziogou listed as a middle author in your input.
    Basis:
    2) Critical appraisal (what could limit inference about author-level capability)
    • Single strongest paper in the provided record. With only one main journal article explicitly supplied in your dataset, author-level “research independence” is difficult to infer. The Nature study is strong, but co-authorship does not prove lead conceptual ownership.
    • Model-to-human generalization. Your excerpt itself flags translational uncertainties such as broader LUAD context coverage and longer-term toxicity/safety for systemic FSP1 inhibition; these are standard gaps when dependency is established in GEMM/xenograft/PDX systems. The inferential leap from “tumor-cell-intrinsic dependency” to “widely effective clinical therapy” remains empirically open.
    • Off-target/compensation and pathway redundancy. Your excerpt notes CRISPR off-target risk and possible redundancy not fully captured by specific in vitro rescue experiments; both issues can inflate effect estimates or miss alternative mechanisms.
    • Selection of cell lines and endpoints. Even with lipidomics and multiple readouts, a limited panel of models can make dependencies appear more uniform than they are across broader patient stratifications.
    These limitations are drawn from your provided “paper_limitations_and_biases” excerpt for the Nature paper:
    3) Reproducibility & transparency signals (from your provided metadata)
    • Raw data availability: your excerpt says raw lipidomic data are deposited in MassIVE and raw gel images are included with the paper; analyzed lipidomics data are in supplementary data.
    • Source-data availability: “Source data are provided with the paper” is asserted in your excerpt.
    Basis:
    4) Conflict-of-interest scrutiny (as provided)
    • Your excerpt reports that at least some senior authors report funding from multiple pharma/industry entities not related to the submitted work, and it reports a patent application filed for some FSP1 inhibitor compounds described in the paper.
    • This does not invalidate the science, but it increases the importance of checking whether effect sizes, model choices, and compound characterization are transparently reported and whether there is independent corroboration.
    Basis:
    5) What would most strengthen (or disprove) the current evidence about Ziogou’s scientific impact?
    • More independently-led first/last-author results (or clear lead contribution in Methods/Conceptualization) across additional ferroptosis-relevant systems.
    • Independent replication of key dependency claims (e.g., FSP1 dependency across broader LUAD cohorts/model panels) using independently generated cohorts or blinded analyses.
    • Mechanistic boundary conditions: tests of where the FSP1/GPX4 axes diverge (cell-state, metabolic context, iron availability, lipid composition), including careful negative findings.
    • Broader immunological mapping: deeper, comprehensive immunomodulatory characterization beyond “modest” immune microenvironment exploration as indicated in your excerpt.
    The “boundary” and “translation” needs are grounded in the limitations you provided:


    Feedback:    

    Updated: March 27, 2026

     Analysis Wizard



    It will extract and QC lipidomic features from the provided MassIVE dataset, then quantify ferroptosis-associated oxidation signatures and test whether FSP1-related perturbations separate sensitive vs resistant samples.



     Hypothesis Graveyard


    The strongest alternative explanation is that tumor suppression from “FSP1 targeting” is primarily due to nonspecific cytotoxic stress unrelated to ferroptosis; this would be disfavored if ferroptosis biomarkers and rescue-by-pathway-specific genetic/pharmacologic interventions remain consistent across model contexts (as your excerpt claims).


    Another weak alternative is that observed effects are driven mainly by immune microenvironment changes rather than tumor-cell-intrinsic dependency; this becomes unlikely if tumor-cell intrinsic manipulations (Gpx4/Fsp1 KO) reproduce key phenotypes even in settings where immune composition is controlled or only modestly impacts outcomes (again, per your excerpt).

     Science Art


    Author Review: Aikaterini Ziogou Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending